How Effective Is Non-Invasive Chromosomal Screening in Hong Kong? NIPT Principles and Clinical Applications

AI Summary Block

Main Content Begins

Reproductive Medicine Perspective · Clinical Decision Reference

In reproductive medicine clinics, patients often come with pregnancy test results and ask, "Doctor, my embryo transfer was successful. Do I need to do non-invasive DNA testing next?" Some naturally pregnant women of advanced maternal age directly ask, "How effective is non-invasive chromosomal screening in Hong Kong, and how is it different from the mainland?" Behind these questions, they all point to the same technology—NIPT (Non-invasive Prenatal Testing).

The application of NIPT in Hong Kong started early, and the testing system is relatively mature. However, patients often have a vague understanding of its positioning, scope of application, and limitations. The following explains the practical value and boundaries of using NIPT in Hong Kong from a clinical decision-making perspective.

1. Basic Principles and Detection Scope of NIPT

NIPT stands for Non-invasive Prenatal Testing. It involves collecting maternal peripheral blood (about 8–10 mL), extracting cell-free fetal DNA (cffDNA) originating from the placenta, and using high-throughput sequencing or gene chip technology to analyze whether the number of chromosomes is abnormal.

Core Detection Scope:

• Trisomy 21 (Down syndrome): Detection rate >99%, false positive rate <0.1%
• Trisomy 18 (Edwards syndrome): Detection rate >97%, false positive rate <0.1%
• Trisomy 13 (Patau syndrome): Detection rate >90%, false positive rate <0.1%
• Sex chromosome abnormalities (some testing platforms): e.g., 45,X (Turner syndrome), 47,XXY (Klinefelter syndrome), etc., with slightly lower accuracy than autosomes
• Some microdeletions/microduplications (expanded version): e.g., 22q11.2 deletion, etc., with variable positive predictive values

2. Clinical Application Characteristics of NIPT in Hong Kong

From a clinical applicability perspective, NIPT in Hong Kong and NIPT in mainland China have no essential difference in technical principles, but there are several practical distinctions:

A practical advantage of NIPT in Hong Kong is the flexibility of the testing process. Patients can have blood drawn directly at an obstetrics and gynecology clinic or fertility center, with samples sent to local or partner laboratories, eliminating the need for multiple hospital visits. For patients traveling from mainland China to Hong Kong for testing, usually only one clinic visit is needed, and reports can be obtained online or by mail.

3. Testing Process and Timeline

3.1 Clinical Process

1. Consultation and Assessment: The doctor confirms gestational age, reviews age, reproductive history, family genetic history, and current pregnancy status.
2. Informed Consent: Explanation of the screening nature of NIPT, detection scope, possible false positives/false negatives, and the management pathway for positive results.
3. Blood Draw: No fasting required; 8–10 mL of peripheral blood is collected using specialized cell-free DNA tubes.
4. Laboratory Testing: Samples are sent to the lab for sequencing or chip analysis.
5. Report Issuance: Reports are generated within 7–10 business days, including risk scores (high risk/low risk) for each chromosome and the fetal fraction.
6. Report Interpretation and Follow-up: The doctor interprets the results; low-risk patients continue routine prenatal care; high-risk patients are scheduled for genetic counseling and amniocentesis.

3.2 Timeline

4. Cost Composition and Influencing Factors

The cost of NIPT in Hong Kong varies clearly between different medical institutions and test versions:

• Basic version (T21+T18+T13): 3000–4500 HKD, suitable for routine prenatal screening needs.
• Expanded version (includes sex chromosomes + common microdeletions): 5000–8000 HKD, suitable for those concerned about sex chromosome abnormalities or with a family history of microdeletions.
• Whole genome scan version: 8000–15000 HKD, covering all chromosomes and known pathogenic microdeletions, but the risk of overdiagnosis needs careful evaluation.

The main sources of cost differences are the licensing fees for testing platforms, laboratory accreditation, and whether genetic counseling is included. NIPT costs in Hong Kong private clinics usually include doctor consultation and blood draw services, while public hospitals may charge separately.

5. Test Indicators and Report Interpretation

The core content of the NIPT report needs to be correctly understood to avoid excessive panic or blind optimism:

5.1 Key Report Indicators

• Fetal fraction: Typically ≥4% is considered adequate; lower values may affect accuracy.
• Z-score (or risk score): Normal range is –3 to +3; values outside this range are marked as high risk.
• Test Result Classification: Low risk = no chromosomal numerical abnormality detected; High risk = suspected chromosomal numerical abnormality, requiring prenatal diagnostic confirmation.

5.2 Common Misconceptions

Misconception 1: A high-risk NIPT result equals a diagnosis. In reality, NIPT is a screening technology with the possibility of false positives. Especially for sex chromosome abnormalities and microdeletions, the positive predictive value (PPV) varies significantly across different age groups. All high-risk NIPT results require confirmation by amniocentesis karyotype analysis or chromosomal microarray (CMA).

Misconception 2: A low-risk NIPT result completely rules out chromosomal abnormalities. NIPT primarily detects chromosomal numerical abnormalities and cannot detect chromosomal structural rearrangements, uniparental disomy, low-level mosaicism, etc. For families with a clear genetic history, targeted genetic testing is still necessary.

6. Suitable and Unsuitable Populations

6.1 Suitable Populations

• Advanced maternal age (delivery age ≥35 years)
• Borderline or high-risk results from serological screening (first/second trimester screening)
• History of pregnancy with fetal chromosomal abnormalities
• Ultrasound findings suggesting fetal structural abnormalities (e.g., increased NT, cardiac malformations, etc.)
• Pregnancy via assisted reproductive technology (including IVF, ICSI, PGT) — PGT cannot fully replace prenatal screening
• Family history of chromosomal abnormalities
• The pregnant woman or her partner is a carrier of a balanced chromosomal translocation (requires combined PGT or prenatal diagnosis)

6.2 Unsuitable or Cautionary Populations

• Gestational age less than 10 weeks: The fetal fraction may be insufficient, leading to a high test failure rate.
• Twin and higher-order multiple pregnancies: NIPT accuracy for twins is lower than for singletons, and it cannot distinguish which fetus has the abnormality. Not recommended for triplets or more.
• Maternal BMI ≥40: Obesity can affect the fetal fraction, increasing the risk of test failure and false negatives.
• Maternal chromosomal abnormality (e.g., 47,XXX, 47,XYY, etc.): May interfere with result interpretation.
• Recent blood transfusion, organ transplant, or immunotherapy: Exogenous DNA may interfere with the test.
• Certain autoimmune diseases: Such as systemic lupus erythematosus, may affect cell-free DNA release.

7. Special Situation Management

7.1 Assisted Reproduction and NIPT

For patients pregnant through in vitro fertilization (IVF), especially those who have undergone preimplantation genetic testing (PGT), some believe that PGT has already screened the chromosomes, making NIPT unnecessary. This view is not entirely correct. PGT tests embryonic trophectoderm cells (3–5 cells), and there is a possibility of missing mosaicism. Additionally, PGT cannot detect chromosomal abnormalities that arise de novo during pregnancy. Therefore, NIPT is still recommended as a supplement to prenatal screening after PGT pregnancy.

7.2 Decision Pathway After a Positive NIPT Result

If the NIPT result is high risk, the standard pathway is:

1. Genetic counseling: A genetic counselor or reproductive specialist explains the meaning of the risk.
2. Amniocentesis: Performed at 16–22 weeks gestation to obtain amniotic fluid cells for karyotype analysis (CMA added if necessary).
3. Wait for karyotype results (usually 2–3 weeks), then decide whether to terminate or continue the pregnancy based on the results.
4. If the karyotype result is normal (false positive), routine prenatal care can continue.

8. Common Consultation Questions

Q: What is the difference between NIPT in Hong Kong and NIPT in mainland China?
The technical principles are the same. Differences mainly lie in testing platform options, cost structure, report interpretation habits, and the follow-up diagnostic referral process. Hong Kong offers more flexible platform choices, shorter turnaround times, and a mature referral process for amniocentesis. NIPT costs in mainland China are relatively lower, and some provinces have included it in medical insurance or centralized procurement.

Q: What materials are needed for NIPT?
Typically required: identification documents (Hong Kong ID card or travel permit), recent ultrasound report (to confirm gestational age and number of fetuses), and previous prenatal records. No fasting is needed, but it is advisable to avoid a high-fat meal immediately before blood draw.

Q: Can NIPT detect all chromosomal problems?
No. NIPT is mainly used to detect chromosomal numerical abnormalities (trisomies, monosomies), and on some platforms, sex chromosome abnormalities and microdeletions. NIPT cannot detect chromosomal structural abnormalities (such as inversions, translocations), single-gene disorders, or polygenic disorders.

Q: How long does it take to get NIPT results?
The standard turnaround time in Hong Kong is 7–10 business days. Some laboratories offer expedited service (5 business days). Samples sent from mainland China may take an additional 1–2 days due to transportation.

9. Doctor's Recommendations

This article is written based on clinical practice in reproductive medicine and is for informational purposes only. It does not constitute medical advice. Please consult a licensed physician for specific testing plans.

NIPT Hong Kong Prenatal Screening Non-invasive DNA Down Syndrome Assisted Reproduction Advanced Maternal Age Chromosomal Abnormality Amniocentesis